Bespoke solutions

We support the companies we work with at all stages of the reimbursement process. We offer knowledge, experience and a professional, flexible approach so that the solutions we propose are appropriate, effective and efficient.

We are the leader on the Polish market, thanks to which the reports we prepare and submit to the Ministry of Health and the Agency for Health Technology Assessment and Tarification (AOTMiT) are always of the highest quality, compliant with both standards and applicable regulations. We support our Partners in contacts with such institutions as the Ministry of Health, the Agency for Health Technology Assessment and the National Health Fund. We prepare them for price negotiations with the Ministry of Health and often participate in these negotiations as substantive and strategic support. We actively participate in various meetings with representatives of the Ministry of Health, the HTA Agency and the National Health Fund.

 

In Poland, we also provide consultations and services in the field of:

  • planning and implementation of reimbursement processes under different funding pathways not only for medicines, but also for medical devices and hospital procedures
  • planning and execution of drug marketing processes under procedures based on the Pharmaceutical Law (including so-called target import);
  • implementation of Early Access Programs.

 

However, MAHTA is not only active on the Polish market. The dynamic development of our organisation and well-developed cooperation on international markets allow us to provide the following services, irrespective of the country chosen:

  • preparation of reimbursement and pricing strategies for medicinal products
  • preparation of our clients for the reimbursement process including a detailed analysis of the documentation and product portfolio
  • preparation of detailed market analyses according to our clients' needs and guidelines

 

We also support our Clients in the following processes:

  • reimbursement of innovative and generic drugs
  • reimbursement of new indications, forms and dosages of medicines
  • price declarations and modifications
  • changes to registration and reimbursement decisions
  • handling local IT systems such as SOLR, iDrug, PCUE or Canamed
  • de novo development and adaptation of reimbursement portfolios according to the requirements of local HTA agencies (NOMA, TLV, NICE, SMC, PBAC, CADTH, INFRAMED).
  • we support global Market Access structures in HEOR activities